Sandoz Canada president explains shortages to House of Commons

Drug shortages brought on by difficulties at Sandoz's Boucherville, Quebec, plant have landed the president of the Novartis ($NVS) subsidiary in the hot seat before a committee of the Canadian House of Commons. Sandoz Canada's Michel Robidoux told members Tuesday that the generic drugmaker is meeting more than 80% of demand in Canada for its products and more than 95% of need for the top half dozen most critical products, reports Postmedia News. A production slowdown at the plant last month in response to FDA concerns have led to shortages of a long list of drugs--including cancer treatments and painkillers. The shortages have ratcheted up calls in Canada for some kind of legislative solution. A March 4 fire at the plant made the situation worse, as the company had to temporarily halt production to clean up. Story | More

Suggested Articles

McCallum was hit with a warning letter from the FDA for testing issues with its products and failing to keep appropriate records.

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.